Advertisement

Topics

FDA expands indication for Eylea to cover all stages of diabetic retinopathy

06:01 EDT 14 May 2019 | Pharmafile

The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy.

Regeneron chief scientific officer George Yancopoulos commented: “with today's FDA approval, Eylea has once again set a high bar for the treatment of diabetic eye diseases.”

read more

Original Article: FDA expands indication for Eylea to cover all stages of diabetic retinopathy

NEXT ARTICLE

More From BioPortfolio on "FDA expands indication for Eylea to cover all stages of diabetic retinopathy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...